SBC Medical Group Holdings Incorporated (NASDAQ:SBC) experienced a sharp decline in its share price on Monday, falling 19.5% after a selling stockholder disclosed the pricing of an underwritten secondary public offering.
According to the filing, Dr. Yoshiyuki Aikawa, identified as the selling stockholder, set the offering at 3,100,000 shares of common stock priced at $3.25 per share. The offering terms include a 45-day option for the underwriters to purchase up to an additional 465,000 shares. The transaction is anticipated to close on or about April 21, 2026, contingent on customary closing conditions.
The company itself is not issuing any shares as part of the transaction and will not receive any of the proceeds; all funds from the sale will go to the selling stockholder. Maxim Group LLC is acting as the sole book-running manager for the deal, while Roth Capital Partners is serving as co-manager.
SBC Medical Group Holdings operates as a Management Services Organization that manages franchise businesses across multiple medical specialties. Its portfolio includes clinics in aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, alopecia treatment, and ophthalmology. The company is pursuing growth in the United States and Asia through a combination of direct operations and medical tourism initiatives.
The company completed its Nasdaq listing in September 2024 and was later selected for inclusion in the Russell 3000 Index in June 2025.
Clear summary - The stock price decline followed the announcement that a selling stockholder has priced a secondary offering of 3,100,000 shares at $3.25 each, with an underwriter option for up to 465,000 additional shares. SBC will not receive proceeds from the sale.
Contextual note - The offering is structured as a secondary sale by an existing holder rather than a primary issuance by SBC Medical Group, and closing is subject to standard conditions on or about April 21, 2026.